AstraZeneca tau txais kev txhawb nqa ob npaug rau nws cov ntaub ntawv kho mob oncology rau hnub Tuesday, tom qab Asmeskas thiab European cov neeg tswj hwm tau txais kev tswj hwm kev xa tawm rau nws cov tshuaj, thawj kauj ruam ntawm kev pom zoo rau cov tshuaj no.
Tus kws tsim tshuaj Anglo-Swedish, thiab MedImmune, nws lub ntiaj teb kev tshawb fawb thiab kev loj hlob caj npab, tshaj tawm tias US Food and Drug Administration (FDA) tau txais daim ntawv tso cai daim ntawv tso cai rau moxetumomab pasudotox, muaj peev xwm tshiab tshuaj rau kev kho mob ntawm cov neeg laus cov plaub hau cell. leukemia (HCL) uas tau txais tsawg kawg yog ob kab ntawm kev kho mob yav dhau los.
FDA tau muab cov tshuaj "ua ntej tshuaj xyuas" cov xwm txheej, uas tau tso cai rau cov tshuaj uas, yog tias pom zoo, yuav muaj kev txhim kho tseem ceeb hauv kev kho mob, kuaj mob, lossis tiv thaiv cov mob hnyav. Kev txiav txim siab xav tau nyob rau lub quarter thib peb ntawm lub xyoo no.
Cais, Lub Koom Haum Saib Xyuas Tshuaj European tau lees txais kev tswj hwm rau Lynparza, cov tshuaj uas AstraZeneca tam sim no koom nrog hauv 50: 50 kev koom tes nrog Merck, Asmeskas cov tuam txhab tshuaj kho mob qog noj ntshav uas kis mus rau lwm qhov hauv lub cev rau cov neeg mob uas muaj qee yam. noob caj noob ces.
Yog tias pom zoo, cov tshuaj yuav dhau los ua thawj PARP inhibitor rau kev kho mob qog noj ntshav hauv Tebchaws Europe. PARP yog cov protein uas muaj nyob hauv tib neeg cov hlwb uas pab cov hlwb kho lawv tus kheej thaum puas. Los ntawm kev tso tseg txoj kev kho no hauv cov qog nqaij hlav cancer, PARP inhibitors pab lub cell tuag.
Lynparza thaum Lub Ib Hlis tau dhau los ua thawj PARP inhibitor pom zoo nyob txhua qhov chaw hauv ntiaj teb rau kev mob qog noj ntshav mis, thaum nws yeej qhov kev mus tom ntej los ntawm Asmeskas cov tswj hwm.
Hauv qhov kev sim zaum kawg, Lynparza tau ua rau muaj kev vam meej tsis muaj sia nyob ntev dua piv nrog cov kws khomob thiab txo qhov kev pheej hmoo ntawm kev kis kab mob lossis tuag los ntawm 42 feem pua.
Hauv 2017 ib feem tsib ntawm Astra cov khoom muag yog los ntawm oncology thiab lub tuam txhab cia siab tias qhov kev faib ua feem yuav nce. Shares hauv pab pawg tau kaw 0.6 feem pua ntawm £ 49.26.
Hauv kev txhim kho cais, Compugen, lub tuam txhab Israeli pharma, tau hais tias nws tau nkag mus rau hauv daim ntawv tso cai tshwj xeeb nrog MedImmune uas yuav pab tsim cov khoom siv tshuaj tiv thaiv kab mob los kho mob qog noj ntshav.
MedImmune muaj txoj cai los tsim ntau yam khoom raws li daim ntawv tso cai "thiab yuav yog lub luag haujlwm rau txhua qhov kev tshawb fawb, kev tsim kho thiab kev ua lag luam raws li kev pom zoo", Compugen tau hais.
Lub tuam txhab Israeli yuav tau txais $ 10m them ua ntej thiab tsim nyog tau txais txog $ 200m hauv kev txhim kho, kev tswj hwm thiab kev lag luam tseem ceeb rau thawj cov khoom lag luam, nrog rau cov nuj nqis ntawm kev muag khoom yav tom ntej.
Anat Cohen-Dayag, tus thawj coj ntawm Compugen, tau hais tias qhov kev pom zoo "tso cai rau peb kom tau txais txiaj ntsig kev tshawb fawb tshwj xeeb hauv peb cov haujlwm, thaum peb txuas ntxiv txhawb peb cov kev coj ua hauv kev sim tshuaj".
Post lub sij hawm: Apr-23-2018